CASE REPORT published: 10 December 2019 doi: 10.3389/fonc.2019.01374 Frontiers in Oncology | www.frontiersin.org 1 December 2019 | Volume 9 | Article 1374 Edited by: Anjali Mishra, Sidney Kimmel Cancer Center, United States Reviewed by: Lisa Jane Russell, Newcastle University, United Kingdom Vincent Van Der Velden, Erasmus Medical Center, Netherlands *Correspondence: André Baruchel andre.baruchel@aphp.fr † These authors have contributed equally to this work Specialty section: This article was submitted to Hematologic Malignancies, a section of the journal Frontiers in Oncology Received: 01 September 2019 Accepted: 21 November 2019 Published: 10 December 2019 Citation: Fournier B, Balducci E, Duployez N, Clappier E, Cuccuini W, Arfeuille C, Caye-Eude A, Delabesse E, Bottollier-Lemallaz Colomb E, Nebral K, Chrétien M-L, Derrieux C, Cabannes-Hamy A, Dumezy F, Etancelin P, Fenneteau O, Frayfer J, Gourmel A, Loosveld M, Michel G, Nadal N, Penther D, Tigaud I, Fournier E, Reismüller B, Attarbaschi A, Lafage-Pochitaloff M and Baruchel A (2019) B-ALL With t(5;14)(q31;q32); IGH-IL3 Rearrangement and Eosinophilia: A Comprehensive Analysis of a Peculiar IGH-Rearranged B-ALL. Front. Oncol. 9:1374. doi: 10.3389/fonc.2019.01374 B-ALL With t(5;14)(q31;q32); IGH-IL3 Rearrangement and Eosinophilia: A Comprehensive Analysis of a Peculiar IGH-Rearranged B-ALL Benjamin Fournier 1† , Estelle Balducci 2† , Nicolas Duployez 3 , Emmanuelle Clappier 4 , Wendy Cuccuini 4 , Chloé Arfeuille 5 , Aurélie Caye-Eude 5 , Eric Delabesse 6 , Elodie Bottollier-Lemallaz Colomb 7 , Karin Nebral 8 , Marie-Lorraine Chrétien 9 , Coralie Derrieux 10 , Aurélie Cabannes-Hamy 11 , Florent Dumezy 3 , Pascaline Etancelin 12 , Odile Fenneteau 13 , Jamile Frayfer 14 , Antoine Gourmel 15 , Marie Loosveld 16 , Gérard Michel 17 , Nathalie Nadal 18 , Dominique Penther 12 , Isabelle Tigaud 19 , Elise Fournier 3 , Bettina Reismüller 20 , Andishe Attarbaschi 20 , Marina Lafage-Pochitaloff 21† and André Baruchel 1,22 * † 1 Department of Pediatric Hematology and Immunology, University Hospital Robert Debré, Assistance Publique des Hôpitaux de Paris (APHP), Paris, France, 2 Hematology Laboratory, University Hospital Paul-Brousse, Assistance Publique des Hôpitaux de Paris (APHP), Villejuif, France, 3 Department of Hematology, University Hospital, Lille, France, 4 Hematology Laboratory, University Hospital Saint-Louis, Assistance Publique des Hôpitaux de Paris (APHP), Paris, France, 5 Department of Genetics, University Hospital Robert Debré, Assistance Publique des Hôpitaux de Paris (APHP), Paris, France, 6 Department of Haematology, Institut Universitaire de Cancérologie de Toulouse, CHU de Toulouse, Toulouse, France, 7 Department of Pediatric Oncology and Hematology, University Hospital of Dijon, Dijon, France, 8 Children’s Cancer Research Institute (CCRI), St. Anna Kinderkrebsforschung, Vienna, Austria, 9 Department of Hematology, University Hospital of Dijon, Dijon, France, 10 Hematology Laboratory, Hospital Saint Faron, Meaux, France, 11 Teenagers and Young Adults Hematology Unit, University Hospital Saint-Louis, Assistance Publique des Hôpitaux de Paris (APHP), Paris, France, 12 Department of Oncology Genetics, Henri Becquerel Center, Rouen, France, 13 Hematology Laboratory, University Hospital Robert Debré, Assistance Publique des Hôpitaux de Paris (APHP), Paris, France, 14 Department of Hematology, Hospital Saint Faron, Meaux, France, 15 Department of Pediatric Oncology, Hematology, Immunology, University Hospital of Amiens, Amiens, France, 16 Hematology Laboratory, Timone Hospital, Assistance Publique-Hôpitaux de Marseille (APHM), CNRS, INSERM, Centre d’Immunologie de Marseille-Luminy (CIML), Aix Marseille University, Marseille, France, 17 Department of Pediatric Hematology, Aix Marseille University, Marseille, France, 18 Laboratory of Cytogenetics, University Hospital of Dijon, Dijon, France, 19 Department of Cytogenetics, Lyon-Sud Hospital, Lyon, France, 20 Department of Pediatric Hematology and Oncology, St. Anna Children’s Hospital, Department of Pediatrics and Adolescent Medicine, Medical University of Vienna, Vienna, Austria, 21 Hematological Cytogenetics Laboratory, Timone Hospital-Assistance Publique-Hôpitaux de Marseille (AP-HM), Aix-Marseille University, Groupe Francophone de Cytogénétique Hématologique (GFCH), Marseille, France, 22 Institut Universitaire d’Hématologie, EA-3518, University Hospital Saint-Louis, Assistance Publique des Hôpitaux de Paris (APHP), Paris, France Background: B-cell acute lymphoblastic leukemia associated with t(5;14)(q31;q32); IGH-IL3 is an exceptional cause of eosinophilia. The IGH enhancer on 14q32 is juxtaposed to the IL3 gene on 5q31, leading to interleukin-3 overproduction and release of mature eosinophils in the blood. Clinical, biological and outcome data are extremely scarce in the literature. Except for eosinophilia, no relevant common feature has been highlighted in these patients. However, it has been classified as a distinct entity in the World Health Organization classification. Cases Presentation: Eight patients with t(5;14)(q31;q32) treated by French or Austrian protocols were retrospectively enrolled. Array comparative genomic hybridization, multiplex ligation-dependent probe amplification or genomic PCR search for IKZF1 deletion were performed in 7. Sixteen patients found through an exhaustive search in the literature were also analyzed.